ERBB2 and breast carcinoma: Ultimately, this literature is of most relevance to breast cancer patients receiving HER2 agents, anthracyclines, and alkylating agents, where the CTRCD of note is cardiomyopathy, witnessed as a depressed LVEF/GLS.